252 related articles for article (PubMed ID: 22314134)
1. A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.
Xiao L; Kim J; Lim M; Dai B; Yang L; Reed SG; Baltimore D; Wang P
Vaccine; 2012 Mar; 30(15):2570-81. PubMed ID: 22314134
[TBL] [Abstract][Full Text] [Related]
2. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.
Orr MT; Duthie MS; Windish HP; Lucas EA; Guderian JA; Hudson TE; Shaverdian N; O'Donnell J; Desbien AL; Reed SG; Coler RN
Eur J Immunol; 2013 Sep; 43(9):2398-408. PubMed ID: 23716300
[TBL] [Abstract][Full Text] [Related]
3. TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion.
Gandhapudi SK; Chilton PM; Mitchell TC
PLoS One; 2013; 8(2):e56855. PubMed ID: 23457630
[TBL] [Abstract][Full Text] [Related]
4. Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.
Seydoux E; Liang H; Dubois Cauwelaert N; Archer M; Rintala ND; Kramer R; Carter D; Fox CB; Orr MT
J Immunol; 2018 Jul; 201(1):98-112. PubMed ID: 29769270
[TBL] [Abstract][Full Text] [Related]
5. MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4.
Cekic C; Casella CR; Sag D; Antignano F; Kolb J; Suttles J; Hughes MR; Krystal G; Mitchell TC
J Immunol; 2011 Apr; 186(7):3858-65. PubMed ID: 21339365
[TBL] [Abstract][Full Text] [Related]
6. A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.
Pantel A; Cheong C; Dandamudi D; Shrestha E; Mehandru S; Brane L; Ruane D; Teixeira A; Bozzacco L; Steinman RM; Longhi MP
Eur J Immunol; 2012 Jan; 42(1):101-9. PubMed ID: 22002164
[TBL] [Abstract][Full Text] [Related]
7. Surface immunogenic protein from Streptococcus agalactiae and
Díaz-Dinamarca DA; Salazar ML; Escobar DF; Castillo BN; Valdebenito B; Díaz P; Manubens A; Salazar F; Troncoso MF; Lavandero S; Díaz J; Becker MI; Vásquez AE
Front Immunol; 2023; 14():1186188. PubMed ID: 37790926
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A.
Embry CA; Franchi L; Nuñez G; Mitchell TC
Sci Signal; 2011 May; 4(171):ra28. PubMed ID: 21540455
[TBL] [Abstract][Full Text] [Related]
9. TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B.
Gaddis DE; Michalek SM; Katz J
J Immunol; 2011 May; 186(10):5772-83. PubMed ID: 21498664
[TBL] [Abstract][Full Text] [Related]
10. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A.
Lambert SL; Yang CF; Liu Z; Sweetwood R; Zhao J; Cheng L; Jin H; Woo J
PLoS One; 2012; 7(12):e51618. PubMed ID: 23284726
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
12. Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF.
Kolb JP; Casella CR; SenGupta S; Chilton PM; Mitchell TC
Sci Signal; 2014 Nov; 7(351):ra108. PubMed ID: 25389373
[TBL] [Abstract][Full Text] [Related]
13. Campylobacter jejuni-induced activation of dendritic cells involves cooperative signaling through Toll-like receptor 4 (TLR4)-MyD88 and TLR4-TRIF axes.
Rathinam VA; Appledorn DM; Hoag KA; Amalfitano A; Mansfield LS
Infect Immun; 2009 Jun; 77(6):2499-507. PubMed ID: 19332531
[TBL] [Abstract][Full Text] [Related]
14. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation.
Shen H; Tesar BM; Walker WE; Goldstein DR
J Immunol; 2008 Aug; 181(3):1849-58. PubMed ID: 18641322
[TBL] [Abstract][Full Text] [Related]
15. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
Mata-Haro V; Cekic C; Martin M; Chilton PM; Casella CR; Mitchell TC
Science; 2007 Jun; 316(5831):1628-32. PubMed ID: 17569868
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.
Davis MB; Vasquez-Dunddel D; Fu J; Albesiano E; Pardoll D; Kim YJ
Clin Cancer Res; 2011 Jun; 17(12):3984-92. PubMed ID: 21543518
[TBL] [Abstract][Full Text] [Related]
17. TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIF.
Kolanowski ST; Dieker MC; Lissenberg-Thunnissen SN; van Schijndel GM; van Ham SM; ten Brinke A
Innate Immun; 2014 May; 20(4):423-30. PubMed ID: 23941760
[TBL] [Abstract][Full Text] [Related]
18. Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant.
Bielinska AU; Makidon PE; Janczak KW; Blanco LP; Swanson B; Smith DM; Pham T; Szabo Z; Kukowska-Latallo JF; Baker JR
J Immunol; 2014 Mar; 192(6):2722-33. PubMed ID: 24532579
[TBL] [Abstract][Full Text] [Related]
19. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.
Lebedeva E; Bagaev A; Pichugin A; Chulkina M; Lysenko A; Tutykhina I; Shmarov M; Logunov D; Naroditsky B; Ataullakhanov R
BMC Immunol; 2018 Jul; 19(1):26. PubMed ID: 30055563
[TBL] [Abstract][Full Text] [Related]
20. TLR4 agonist activity of Alcaligenes lipid a utilizes MyD88 and TRIF signaling pathways for efficient antigen presentation and T cell differentiation by dendritic cells.
Sun X; Hosomi K; Shimoyama A; Yoshii K; Lan H; Wang Y; Yamaura H; Nagatake T; Ishii KJ; Akira S; Kiyono H; Fukase K; Kunisawa J
Int Immunopharmacol; 2023 Apr; 117():109852. PubMed ID: 36806039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
